In the present study we aimed to demonstrate the efficacy of short-term pretreatment with finasteride in patients undergoing transurethral resection of the prostate (TUR-P). For this purpose 40 patients with BPH, who were candidates for TUR-P, were randomized into two groups. The first group (n ¼ 20) received 5 mg finasteride/day for 4 weeks prior to surgery and the second group (n ¼ 20) remained as the control. Patients who underwent prior prostate or urethral surgery and had a diagnosis of prostate cancer or chronic renal failure, patients who received finasteride, aspirin, coumadin or similar anticoagulant drugs prior to surgery and patients who had capsule perforations or open sinuses during the surgery were excluded from the study. All patients had a normal digital rectal examination and PSA values less than 4 ng/ml. As we look at the results there was no statistically significant difference between the finasteride group and control group regarding age, IPSS, PSA, prostate volumes, preoperative serum hemoglobin, hematocrit values and mean operating times and used irrigating fluids. The total amount of bleeding and bleeding per gram resected tissue were significantly lower in the finasteride group regardless of prostate volume. Furthermore the decrease in the hemoglobin and hematocrit values was higher in the control group. As a conclusion four weeks of finasteride pretreatment provided a significant decrease in peroperative bleeding regardless of prostate volume without any major side effects.
Introduction
Transurethral resection of the prostate (TUR-F) remains a gold standard procedure for the treatment of urinary obstructive symptoms due to BPH in most centers. The most prevalent peroperative and postoperative complications of TUR-P are urinary retention, significant bleeding which require transfusion and clot retention. Blood loss is one of the most important causes of morbidity during TUR-P. 2 It has been previously demonstrated that androgen deprivation induces a marked involution of the vasculature in rat prostate and testosterone treatment rapidly reverses this process.
3-5 The effect of finasteride, which is a 5-alpha-reductase inhibitor, on prostatic bleeding due to BPH is well documented. It also decreases the incidence of surgery and acute retention besides limiting hematuria in patients with BPH. [6] [7] [8] Animal and human studies with finasteride established a reduction in prostatic blood flow and vascular density, 9, 10 which is probably related with the downregulation of vascular endothelial growth factors. Furthermore, patients with hematuria have elevated concentration of blood vessels in the suburethral tissue of the prostatic urethra, which presumably bleed after excursion. 3, 11, 12 In a randomized controlled study performed by Foley et al 13 reported that finasteride is effective in prostatic bleeding when compared to control group.
In the present study we evaluated the effect of shortterm finasteride therapy on peroperative bleeding in BPH patients undergoing TUR-P.
Methods
Between 2003 and 2004, 40 patients with lower urinary tract symptoms with BPH who were candidates for surgery were included in this prospective study. The patients were randomized into two groups. In the first group 20 patients received finasteride 5 mg/day for 4 weeks prior to surgery and 20 patients in the second group remained as the controls. Patients who underwent prior prostate or urethral surgery and had a diagnosis of prostate cancer or chronic renal failure, patients who received finasteride, aspirin, coumadin or similar anticoagulant drugs prior to surgery and patients who had capsule perforations or open sinuses during the surgery were excluded from the study. Past medical history, International Prostatic Symptom Scores (IPSS) and potency status were recorded. All the patients had normal digital rectal examinations and PSA values less than 4 ng/ml. Prostate volumes were calculated under transrectal ultrasound. All the operations were performed under either spinal or epidural anesthesia. The TUR-Ps were performed by the same surgeon (KB) blindly, using a 24F resectoscope (Karl Storz, Tuttlingen, Germany). While performing TUR-P, 1.5% glycine irrigation fluid (Eczacibasi Corp., Turkey) was used and 1000 U of heparin was added to the collecting buckets for to prevent coagulation. The amounts of irrigation fluid used were recorded and 4 cm 3 samples were taken from the upper part of the returned irrigant fluid in the collecting bucket for hemoglobin (hb) determination. Additionally, serum hb and hematocrite (hct) counts were performed synchronously. The amount of bleeding was calculated with the hemocue method as described previously.
14 All the prostatic tissue removed was weighed and dispatched for histopathological examination. All the data were analyzed with SPSS software for windows. Independent t-test was used to compare the two groups. P-values less than 0.05 were considered as statistically significant.
Results
The mean ages in the finasteride group and control group were 66.979.43 and 66.3075.18 y respectively (Table 1) . The mean age, IPSS, PSA, prostate volumes, preoperative serum hb and hct, in the finasteride and control group were similar in both groups (Tables 1 and  2 ). There wasn't any statistically significant difference between the finasteride group and the control group regarding age, IPSS, PSA, prostate volumes, preoperative serum hb and hct values. The mean irrigating fluid volumes in the finasteride and control group were 19 32577 217 and 18 660710 307 ml, respectively (P40.05, Table 2 ). Additionally, the mean operating time was 6377.56 min in the finasteride group and 5776.92 min in the control group (P40.05). We also measured the hb concentration in the irrigating fluid in the finasteride and the control group, which were 0.12370.744 and 0.17870.106 g/dl, respectively (Table 2) .
Although the hb concentration in the irrigating fluids seemed similar, when we calculated the amount of bleeding in both groups, there was a significant increase in the control group.
The amounts of bleeding calculated by the formula (irrigating fluid volume Â hemoglobin concentration in the irrigating fluid/preoperative serum hb) in the finasteride and control group which were 173.47786.18 and 235.46767.03 ml, respectively (Po0.05, Table 3 ). The weights of the resected prostate tissue in the finasteride and the control groups were 23.25710.4 and 18.7376.63 g respectively (Table 3) . Subsequently, we calculated the amounts of bleeding per resected gram of prostate tissue in the finasteride and the control group, which was 7.672.37 and 13.9974.16 ml, respectively. The amount of bleeding per gram resected prostate tissue was significantly higher in the control group (Po0.0001, Table 3 ).
The postoperative hb and hct values were determined and the preoperative and postoperative changes were evaluated. There was a significant decrease in hb and hct values in both groups in the early postoperative period, but the decrease in the finasteride group was significantly lower when compared to the control group (Po0.0001, Table 3 ). In the early postoperative period none of the patients required blood transfusion, whereas in the control group two patients received blood transfusion, because of prolonged bleeding.
No major complication was observed in the peroperative and early postoperative period. Erectile impotence was observed in one patient (5%) and decreased libido in 
Discussion
Early animal studies demonstrated that castration induces a rapid decrease in the blood flow of the ventral prostate and the decrease in the blood flow precedes apoptosis, which was evident at 2-3 days after castration. 4 Furthermore, as outlined in the Introduction, animal and human studies with finasteride established a reduction in prostatic blood flow and vascular density. 9, 10 It is well known that finasteride reduces size of the prostate gland, and this process may take up to 6 months. 15, 16 Puncher et al 7 stated that finasteride decreases the androgen-derived growth factors responsible for angiogenesis in the prostate which lead to bleeding by inhibiting the conversion of testosterone to dihydrotesyosterone. Additionally finasteride has a downregulatory effect on fibroblastic growth factor, epidermal growth factor and vascular endothelial growth factor which are androgen dependant. [17] [18] [19] [20] Foley and Bailey reported that there was an increase in the microvessel density in the suburethral tissue of the prostatic urethra in men with BPH and hematuria when compared to men without hematuria. 21 It is also stated that hematuria associated with BPH resolved in two weeks after finasteride treatment. 16 Previous reports have demonstrated that preoperative administration of finasteride for 3 months prior to TUR-P decreases peroperative bleeding in prostates larger than 30 g and there was not much significant difference with the control group in smaller prostates. 22 However in the present study we demonstrated that short-term administration of finasteride is effective in reducing blood loss regardless of prostatic volume in as short a time as 4 weeks. Additionally, there wasn't any statistically significant difference between the finasteride and the control groups regarding prostate volume and the amount of resected tissue.
The amount of bleeding per gram resected tissue was significantly lower in the finasteride group when compared to the controls (7.6072.37 vs 13.9974.16 ml/ g) (Po0.0001). In the study conducted by Sandfeldt et al 23 a positive correlation between blood loss and resection weights was reported. Additionally, they proposed that for prostates with resection weights greater than or equal to 18.6 g, finasteride was associated with less blood loss than in controls. In this study, finasteride was administered for 3 months and there was a decrease in the mean prostatic volume. On the contrary, in our study the effect of finasteride was regardless of prostate volume and four weeks of pretreatment with finasteride was effective in decreasing peroperative bleeding.
In the present study, there was a significant decrease in the postoperative hb and hct levels in the control group when compared to the finasteride group (Po0.0001), which indicates that, finasteride may potentially result to decrease complications related to blood loss. Similarly, Donohue et al 24 reported an increased hb loss in the placebo group whereas the finasteride group had a lesser amount of hb loss.
No blood transfusion was needed in the finasteride group whereas two patients received 2 U of blood after surgery. Blood transfusion (3.9%), postoperative gross hematuria and clot retention (3.3%) related to TUR-P, which was reported by Mebust et al, 1 are relatively subjective issues whereas the amount of bleeding per gram resected tissues seems to be a more effective criterion for to determine and compare peroperative bleeding.
The 4 weeks of administration of finasteride is well tolerated and might be advised for patients with cardiac risk who were more susceptible to blood loss. Decreased libido and impotence were seen in few patients, resolved in 3 months following surgery; impotence might be a complication of the TUR-P itself.
Conclusions
In the present study short-term pretreatment with finasteride provided a significant decrease in bleeding per gram resected tissue regardless of prostate volume without major side effects. Pretreatment with finasteride has a potential effect on decreasing the need for blood transfusion by decreasing the peroperative blood loss. The short-term therapy with finasteride is relatively inexpensive and well tolerated by patients and has no major side effects. We believe that 4 weeks of administration of finasteride particularly in high risk patients prior to surgery may have the potential to decrease the complications related to blood loss. Effect of finasteride on preoperative bleeding ÖL Özdal et al
